Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
The DOI matches its Crossref record; 484 of the 491 references it cites were found in a registry or an index.
Abstract
Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the beneficial effects of metformin are increasingly evident, especially when combined with lifestyle modifications, improving the pathogenetic mechanisms underlying PCOS, restoring ovarian function, and improving metabolic profile, especially insulin sensitivity and, unlike COCs, lipoprotein pattern [49].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [49]
In the citing paper
“Metformin has been used extensively in DM2, is the most studied in PCOS, and has the most reassuring safety profile. 222”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [222]
Citations
Cites
4 retracted
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M.-H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 478
RetractedClomiphene citrate for ovulation induction in women with oligo-amenorrhoea
Hughes, E. G., Collins, J. A., & Vandekerckhove, P. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000056 · Cited by 75
RetractedWei, Z., Cao, Y., Cong, L., Zhou, P., Zhang, Z., & Li, J. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1385 · Cited by 37
RetractedKoçak, İ., & Üstün, C. (2006) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2006.00401.x · Cited by 24
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Research works printed but not linked: 5
- 2005, American Association of Clinical Endocrinologists position statements on metabolic and cardiovascular consequences of polycystic ovary syndrome., Endocr Pract, 11, 126
- Deaton, 1991, Hyperandrogenism and uterine bleeding., Infertil Reprod Med Clin North Am, 2, 561
- 1992, Recent advances in medically assisted conception., WHO Tech Rep Ser, 820, 1
- Sonntag, 2005, Metformin alters insulin signaling and viability of human granulosa cells., Fertil Steril, 84, 1173, 10.1016/j.fertnstert.2005.04.043 · DOI
- Koschinsky, 1988, Influence of metformin on vascular cell proliferation., Diabetes Metab, 14, 566
Cited by
Items 101–200 of 426
Cupisti, S., Giltay, E. J., Gooren, L. J., Kronawitter, D., Oppelt, P. G., Beckmann, M. W., Dittrich, R., & Mueller, A. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.03.048 · Cited by 61
AlHussain, F., AlRuthia, Y., Al-Mandeel, H., Bellahwal, A., Alharbi, F., Almogbel, Y., Awwad, O., Dala'een, R., & Alharbi, F. A. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s244273 · Cited by 53
Li, X., Cui, P., Jiang, H., Guo, Y.-R., Pishdari, B., Hu, M., Feng, Y., Billig, H., & Shao, R. (2015) · PubMed Central · Cited by 67
Gambineri, A., Tomassoni, F., Gasparini, D. I., Di Rocco, A., Mantovani, V., Pagotto, U., Altieri, P., Sanna, S., Fulghesu, A. M., & Pasquali, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0145 · Cited by 53
Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature
Palomba, S., Colombo, C., Busnelli, A., Caserta, D., & Vitale, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251866 · Cited by 73
Self-citationCheraghi, E., Mehranjani, M. S., Shariatzadeh, S. M. A., Nasr‐Esfahani, M. H., & Ebrahimi, Z. (2014) · Reproduction Fertility and Development · doi:10.1071/rd14182 · Cited by 59
“induce regular menstrual cycles and increase the ovulation rate by approximately 75% in patients with PCOS (Palomba et al. 2009).”
BackgroundPolycystic ovary syndrome and the peripheral blood white cell count
Herlihy, A. C., Kelly, R. E., Hogan, J. L., O'Connor, N., Farah, N., & Turner, M. J. (2011) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2011.553693 · Cited by 52
“Several studies have reported an association between PCOS and low-grade chronic inflammation, but there is uncertainty about whether the inflammation is due to the PCOS itself or to the associated obesity (Palomba et al. 2009).”
BackgroundPalomba, S., Falbo, A., Russo, T., Rivoli, L., Orio, M., Cosco, A. G., Vero, R., Capula, C., Tolino, A., Zullo, F., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1971 · Cited by 51
“In PCOS women, insulinsensitizing drugs, such as metformin, have been proven to be effective on hormonal and metabolic features of the syndrome (32).”
BackgroundSelf-citationYang, P.-K., Hsu, C.-Y., Chen, M.-J., Lai, M.-Y., Li, Z.-R., Chen, C.-H., Chen, S.-U., & Ho, H.-N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01739 · Cited by 52
“Whether the effects of metformin on LH result from insulin-dependent or insulin-independent pathways remains uncertain (40), but much less is known about latter.”
BackgroundUse of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Shan, B.-E., Ren, Y.-L., Sun, J.-M., Tu, X.-Y., Jiang, Z.-X., Ju, X., Zang, R., & Wang, H.-Y. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2826-8 · Cited by 51
31. Polycystic ovary syndrome and the metabolic syndrome
Hunter, T., & Hart, R. J. (2014) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-767-7.031 · Cited by 51
Mazza, A., Fruci, B., Guzzi, P. H., D'Orrico, B., Malaguarnera, R., Veltri, P., Fava, A., & Belfiore, A. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.04.016 · Cited by 55
“In particular, the antidiabetic drug metformin may decrease insulin resistance and serum androgen levels and ameliorate the ovarian function [2].”
BackgroundTHERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0585 · Cited by 49
Velija-Ašimi, Z. (2013) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2013.2359 · Cited by 53
Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A. (2012) · Human Reproduction · doi:10.1093/humrep/des262 · Cited by 48
Reproductive tract function and dysfunction in women
Roy, A., & Matzuk, M. M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.79 · Cited by 54
“However, because of the high prevalence of insulin resistance in women with PCOS, metformin (an insulin sensitizer) has emerged as a major treatment option to help regulate the menstrual cycle and other metabolic abnormalities in women with PCOS”
BackgroundHilli, M. M. A., Bakkum-Gamez, J. N., Mariani, A., Cliby, W. A., Gree, M. E. M., Weaver, A. L., Dowdy, S. C., & Podratz, K. C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.019 · Cited by 46
Contemporary approaches to the management of polycystic ovary syndrome
Pasquali, R. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818756790 · Cited by 63
Polycystic ovary syndrome: A review for dermatologists
Buzney, E. A., Sheu, J., Buzney, C. D., & Reynolds, R. V. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.009 · Cited by 56
“In 1 study, 6 months of metformin reduced acanthosis nigricans but only minimally affected hirsutism and acne,(55,160) while another reported no impact on acanthosis nigricans.(147,161) Thiazolidinediones Thiazolidinediones (TZDs) suppress gluconeogenesis by increasing peripheral glucose uptake and decreasing hepatic…”
BackgroundInsulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update
Katsiki, N., & Hatzitolios, A. I. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833e1264 · Cited by 52
Marca, A. L., Grisendi, V., Dondi, G., Sighinolfi, G., & Cianci, A. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.964201 · Cited by 50
Palomba, S., Falbo, A. I., Cello, A. D., Cappiello, F., Tolino, A., & Zullo, F. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.08.020 · Cited by 48
Self-citationVictor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Castelló, R., Falcón, R., Gómez, M., Rocha, M., & Hernández-Mijares, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0572 · Cited by 44
“It exerts multiple actions on different 60 tissues affected by hyperinsulinemia and/or IR, such as adipose tissue, skeletal muscle, 61 liver, endothelium and ovaries [7], and seems to improve the long-term health outcome 62 of women with PCOS by preventing endometrial cancer, diabetes and cardiovascular 63 disease [8].”
BackgroundInvestigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model
Karateke, A., Dokuyucu, R., Doğan, H., Özgür, T., Taş, Z. A., Tutuk, O., Ağtürk, G., & Tümer, C. (2018) · Medical Principles and Practice · doi:10.1159/000494300 · Cited by 50
Metformin for the Treatment of Hyperandrogenism in Adolescents with Type 1 Diabetes Mellitus
Codner, E., Iñíguez, G., López, P., Mujica, V., Eyzaguirre, F. C., Asenjo, S., Torrealba, I., & Cassorla, F. (2013) · Hormone Research in Paediatrics · doi:10.1159/000355513 · Cited by 42
Polycystic ovary syndrome: chemical pharmacotherapy
Rocca, M. L., Venturella, R., Mocciaro, R., Cello, A. D., Sacchinelli, A., Russo, V. M., Trapasso, S., Zullo, F., & Morelli, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047344 · Cited by 43
“It has pleiotropic -sensitizing actions [243] through which improves fasting and glucose-stimulated insulin, reduces ovarian androgen production [244] and circulating androgen [95,138].”
BackgroundSelf-citationPhysiological role and clinical utility of inositols in polycystic ovary syndrome
Bevilacqua, A., & Bizzarri, M. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.03.007 · Cited by 45
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Yen and Jaffe's Reproductive Endocrinology · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 36
Metformin and the risk of endometrial cancer: A population-based cohort study
Ko, E. M., Stürmer, T., Hong, J., Castillo, W. C., Bae-Jump, V. L., & Funk, M. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.001 · Cited by 50
“treat menstrual dysfunction and infertility in women with polycystic ovarian syndrome [7,8].”
BackgroundFruzzetti, F., Perini, D., Lazzarini, V., Parrini, D., Gambacciani, M., & Genazzani, A. R. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.10.016 · Cited by 42
Martinez, J. A., Chalasani, P., Thomson, C. A., Roe, D., Altbach, M., Galons, J.-P., Stopeck, A., Thompson, P. A., Villa-Guillen, D. E., & Chow, H.-H. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2551-3 · Cited by 41
“In women with PCOS, metformin has been shown to reduce circulating insulin levels (reviewed by [11]), increase insulin-like growth factor binding protein (IGF-BP) 1 [15, 16], decrease serum testosterone and androstenedione levels [17, 18], and increase serum sex steroid hormone binding globulin [17, 18].”
InfluentialWang, F., Wang, S., Zhang, Z., Lin, Q., Liu, Y., Xiao, Y., Xiao, K.-Z., & Wang, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7678 · Cited by 45
“An increasing number of studies have demonstrated that DMBG modulates the insulin sensitivity and glucose metabolism of its target tissues in women with PCOS (24,25).”
Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., & Guido, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13304 · Cited by 40
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00017-1 · Cited by 49
Pradas, I., Rovira‐Llopis, S., Naudí, A., Bañuls, C., Rocha, M., Hernández‐Mijares, A., Pamplona, R., Víctor, V. M., & Jové, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52263-w · Cited by 45
A guide to understanding polycystic ovary syndrome (PCOS)
Duncan, W. C. (2014) · Journal of Family Planning and Reproductive Health Care · doi:10.1136/jfprhc-2012-100505 · Cited by 46
“41 42 It can improve feelings of wellbeing, ovarian cyclicity and fertility as a main or as adjunct therapy.”
BackgroundPostmenopausal breast cancer, androgens, and aromatase inhibitors
Campagnoli, C., Pasanisi, P., Castellano, I., Abbà, C., Brucato, T., & Berrino, F. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2505-2 · Cited by 42
Ge, J. J., Wang, D., Song, W., Shen, S., & Ge, W. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01666-6 · Cited by 49
Magzoub, R., Kheirelseid, E. A. H., Perks, C. M., & Lewis, S. J. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2022.01.025 · Cited by 49
Maternal polycystic ovarian syndrome and early offspring development
Bell, G. A., Sundaram, R., Mumford, S. L., Park, H., Mills, J. L., Bell, E. M., Broadney, M. M., & Yeung, E. H. (2018) · Human Reproduction · doi:10.1093/humrep/dey087 · Cited by 44
“…findings, but use of metformin during pregnancy is generally considered safe, and results of our study are consistent with prior studies suggesting no harm to the developing fetus, and likely benefits in reducing complications (Cassina et al., 2014; Palomba et al., 2009; Syngelaki et al., 2016).”
Physiology of the female reproductive axis
Bates, G. W., & Bowling, M. R. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00409.x · Cited by 48
Status of clomiphene citrate and metformin for infertility in PCOS
Misso, M. L., Teede, H. J., Hart, R. J., Wong, J., Rombauts, L. J. F., Melder, A., Norman, R. J., & Costello, M. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.07.001 · Cited by 39
Yang, Y., Zhou, C.-C., Hu, H., Fukuzawa, I., & Zhang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1035929 · Cited by 39
“Metformin, an insulin sensitizer, has been widely used for the treatment of PCOS patients (17).”
BackgroundTargeting insulin sensitivity in the treatment of polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903190699 · Cited by 35
“Increased intrauterine vascularity and endometrial receptivity have also been found during metformin treatment in infertile women with PCOS, and have been attributed to several factors, including lowered circulating insulin, improved activity of the androgen receptors, decreased IGF-1 and changes in glycodelin concent…”
InfluentialKilic, S., Yilmaz, N., Zulfikaroglu, E., Erdogan, G., Aydin, M., & Batioglu, S. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.530706 · Cited by 35
Life-style and metformin for the prevention of endometrial pathology in postmenopausal women
Campagnoli, C., Abbà, C., Ambroggio, S., Brucato, T., & Pasanisi, P. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.706671 · Cited by 47
“Insulin stimulates the ovary and adrenal cortex production of androgens (especially androstenedione and testosterone) through the 17α-hydroxylase and 17,20-lyase activities [47].”
BackgroundEndothelial maintenance in health and disease: Importance of sex differences
Mudrovcic, N., Arefin, S., Craenenbroeck, A. H. V., & Kublickiene, K. R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.011 · Cited by 38
“[168] Palomba S, Falbo A, Zullo F, Orio FJ.”
BackgroundInfluentialKupreeva, M., Diané, A., Lehner, R. S., Watts, R., Ghosh, M., Proctor, S. D., & Vine, D. F. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00018.2018 · Cited by 36
Palomba, S., Falbo, A., Battista, L., Russo, T., Venturella, R., Tolino, A., Orio, F., & Zullo, F. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.11.042 · Cited by 33
Self-citationMetformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0311-1 · Cited by 39
Swanton, A., Lighten, A. D., Granne, I., McVeigh, E., Lavery, S. A., Trew, G. H., Talmor, A. J., Raine‐Fenning, N., Jayaprakasan, K., & Child, T. J. (2011) · Human Reproduction · doi:10.1093/humrep/der120 · Cited by 32
“Insulin-sensitizing agents, such as metformin, have been used alone to try and promote ovulation and conception in women with PCOS, though the effects appear limited (Palomba et al., 2009; Tang et al., 2009).”
BackgroundAnti-Müllerian Hormone Is Not Associated with Cardiometabolic Risk Factors in Adolescent Females
Anderson, E. L., Fraser, A., McNally, W., Sattar, N. A., Lashen, H., Fleming, R., Nelson, S. M., & Lawlor, D. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064510 · Cited by 34
“Hyperinsulinaemia has been proposed as a possible mechanism that may disrupt normal follicular development, [50] with polycystic ovary syndrome associated with both hyperinsulinaemia T a b le 2 .”
BackgroundThe role of alpha lipoic acid in female and male infertility: a systematic review
Tucci, C. D., Galati, G., Mattei, G., Bonanni, V., Capri, O., D'Amelio, R., Muzii, L., & Panici, P. B. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1843619 · Cited by 36
“There is a growing consensus around the usefulness of metformin as an insulin-sensitizer [34,35], but its use is limited by possible gastrointestinal side effects [35,36].”
BackgroundImpact of Metformin on Male Reproduction
Ferreira, C., Sousa, M., Rabaça, A., Oliveira, P. F., Alves, M. G., & Sá, R. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710150041 · Cited by 34
Salloum, B. A., Herkimer, C., Lee, J. S., Veiga‐Lopez, A., & Padmanabhan, V. (2012) · Endocrinology · doi:10.1210/en.2011-2074 · Cited by 32
Xue, J., Zhang, H., Liu, W. Y., Liu, M., Shi, M., Wen, Z., & Li, C. (2013) · Reproduction · doi:10.1530/rep-13-0135 · Cited by 35
Ou, H.-T., Chen, P.-C., Wu, M.-H., & Lin, C.-Y. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0520-9 · Cited by 31
“, acne) [32, 33].”
Jamilian, M., Farhat, P., Foroozanfard, F., Afshar Ebrahimi, F., Aghadavod, E., Bahmani, F., Badehnoosh, B., Jamilian, H., & Asemi, Z. (2017) · Clinical Endocrinology · doi:10.1111/cen.13366 · Cited by 31
Mahamed, R. R., Maganhin, C. C., Sasso, G. R. D. S., Simões, M. D. J., Baracat, M. C. P., Baracat, E. C., & Soares, J. M. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0392-1 · Cited by 34
“The genesis and pathophysiology of these changes are known to be related to hyperandrogenism [2].”
BackgroundMeneghini, C., Bianco, C., Galanti, F., Tamburelli, V., Lago, A. D., Licata, E., Gallo, M., Fabiani, C., Corno, R., Miriello, D., et al. (2023) · Nutrients · doi:10.3390/nu15204444 · Cited by 39
“Thus, addressing the obesity/overweight condition could lead to a decrease in the risk of abortion, gestational diabetes mellitus, pregnancy-induced hypertension, preeclampsia, and poor infant outcomes [1,6,7].”
BackgroundLi, X., & Shao, R. (2014) · Europe PMC (PubMed Central) · Cited by 48
Thiazolinedione treatment in PCOS – an update
Glintborg, D., & Andersen, M. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.491572 · Cited by 34
“OC treatment is more efficient than metformin treatment regarding hirsutism and acne and improvement of menstrual cycles [97,98].”
BackgroundTargeting angiogenesis in the pathological ovary
Duncan, W. C., & Nio‐Kobayashi, J. (2012) · Reproduction Fertility and Development · doi:10.1071/rd12112 · Cited by 32
Use of metformin in pediatric age
Brufani, C., Fintini, D., Nobili, V., Patera, P. I., Cappa, M., & Brufani, M. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00741.x · Cited by 35
“Its use may also improve hirsutism (7, 40), even if metformin is not the most efficacious approach in ameliorating hirsutism.”
BackgroundMetformin treatment for Type 2 diabetes in pregnancy?
Simmons, D. S. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.002 · Cited by 32
Pourghasem, S., Bazarganipour, F., Taghavi, S. A., & Kutenaee, M. A. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05064-5 · Cited by 28
Insulin Sensitizers in Polycystic Ovary Syndrome
Pasquali, R., & Gambineri, A. (2012) · Frontiers of hormone research · doi:10.1159/000341837 · Cited by 30
Valsamakis, G., Lois, K., Kumar, S., & Mastorakos, G. P. (2013) · HORMONES · doi:10.1007/bf03401302 · Cited by 30
Falbo, A. I., Rocca, M. L., Russo, T., D'Ettore, A., Tolino, A., Zullo, F., Orio, F., & Palomba, S. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-16 · Cited by 32
“Metformin, an insulin-sensitizing drugs recently introduced for the treatment of women with PCOS, has been demonstrated to induce regular menstrual cycles and to increase ovulation in patients with PCOS, although the efficacy of the drug is extremely variable both between different PCOS populations and within the same…”
BackgroundSelf-citationLi, Y., Wang, L., Xu, J., Niu, W., Shi, H., Hu, L., Zhang, Y., Zhang, M., Bao, X., Zhang, N., et al. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.01.026 · Cited by 28
Andræ, F., Abbott, D. H., Stridsklev, S., Schmedes, A., Odsæter, I. H., Vanky, E., & Salvesen, Ø. O. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa605 · Cited by 31
“SBP (mmHg) 118 (12) 119 (12) 117 (11) 114 (12) 0.”
BackgroundInfluentialLi, X., Hu, S., Zhu, Q., Yao, G., Yao, J., Li, J., Wang, Y., Ding, Y., Qi, J., Xu, R., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154749 · Cited by 26
Study of lipid profile in adult women with acne
Fonseca, F. L. A., Macedo, M., da Cunha, M. G., Machado, C. D. A. S., & Batista, A. A. S. (2015) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s83248 · Cited by 31
“The increase of androgen levels, insulin secretion, PCOS as well as dyslipidemia are under genetic control according to what has been established in familial studies.(13,20,21) Still, Table 3 HDL profile of adult women with acne”
Albaghdadi, A. J. H., & Kan, F. W. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062872 · Cited by 28
“Additionally, combined oral contraceptive pills (OCPs) have been used to improve hyperandrogenism in women with PCOS [75], and for its demonstrated clinical and metabolic benefits improving ovulation and menstrual frequency in anovulatory PCOS patients, the insulin-sensitizing agent metformin has also been prescribed…”
BackgroundWitchel, S. F., Recabarren, S. E., González, F., Diamanti‐Kandarakis, E., Cheang, K. I., Dulęba, A. J., Legro, R. S., Homburg, R., Pasquali, R., Løbo, R. A., et al. (2012) · Endocrine · doi:10.1007/s12020-012-9701-4 · Cited by 30
Glintborg, D., Mumm, H., Holst, J. J., & Andersen, M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0034 · Cited by 26
Moro, F., Morciano, A., Tropea, A., Sagnella, F., Palla, C., Scarinci, E., Ciardulli, A., Martínez, D., Familiari, A., Liuzzo, G., et al. (2013) · Reproductive Sciences · doi:10.1177/1933719113488444 · Cited by 27
“Abnormal ovarian function, including excessive androgen production, is considered to be a pathophysiological key feature of PCOS.”
BackgroundInfluentialMiyoshi, A., Nagai, S., Takeda, M., Kondo, T., Nomoto, H., Kameda, H., Hirai, A., Cho, K., Kimachi, K., Shimizu, C., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12040 · Cited by 25
Genazzani, A. D., Chierchia, E., Rattighieri, E., Santagni, S., Casarosa, E., Luisi, M., & Genazzani, A. R. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.500818 · Cited by 26
Jin, J., Yang, Y., Zhu, X., Han, D. H., Liu, H., & Xie, S. (2018) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2018.05.023 · Cited by 27
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Przybycień, P., Gąsior‐Perczak, D., & Placha, W. (2022) · Cells · doi:10.3390/cells11162569 · Cited by 29
“Metfomin (1,1-dimethylbuguanide hydrochloride) is an insulin sensitizer that shows benefits in managing PCOS-related disorders, especially in overweight and obese patients [62].”
BackgroundGlintborg, D., Mumm, H., Altinok, M. L., Richelsen, B., Bruun, J. M., & Andersen, M. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0103-8 · Cited by 28
“via weight loss and decreased fat mass [26] and could explain the limited effects of 3–6 months metformin treatment on adiponectin levels [35, 36].”
BackgroundShao, F., Li, Y., & Zhao, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1139858 · Cited by 23
Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome
Khan, M. S., Kim, H., Kim, R., Yoon, S. H., & Kim, S. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087454 · Cited by 27
Vaggopoulos, V., Trakakis, E., Chrelias, C. G., Panagopoulos, P., Basios, G., MAKRIDIMA, S., Sioulas, V. D., SIMEONIDES, G., Labos, G., Boutati, E. I., et al. (2013) · Journal of Endocrinological Investigation · doi:10.3275/8771 · Cited by 23
Cheng, F., Zhao, L., Wu, Y., Huang, T., Yang, G., Zhang, Z., Wu, Y., Jia, F., Wu, J., Chen, C., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12950 · Cited by 27
Kaya, M. G., Çalapkorur, B., Karaca, Z., Yıldırım, S., Çelik, A., Akpek, M., Ünlühızarcı, K., & Keleştimur, F. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04436.x · Cited by 24
Insulin-induced capillary recruitment is impaired in both lean and obese women with PCOS
Ketel, I. J. G., Serné, E. H., IJzerman, R. G., Korsen, T. J. M., Twisk, J. W. R., Hompes, P. G. A., Smulders, Y. M., Homburg, R., Vorstermans, L., Stehouwer, C. D. A., et al. (2011) · Human Reproduction · doi:10.1093/humrep/der296 · Cited by 25
Fruzzetti, F., Capozzi, A., Canu, A., & Lello, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540573 · Cited by 31
“However, the use of metformin may be limited by possible gastrointestinal side effects [9, 10].”
BackgroundYang, K., Zeng, L., Bao, T., Long, Z., & Jin, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-54408-3 · Cited by 25
Mohamed, A. H., Albasheer, O., Ghoniem, M. A., Abdalghani, N., Ayish, F., Abdelwahab, S. İ., Abdelmageed, M. M., Hakami, A., Khormi, A. H., Altraifi, A. A. A., et al. (2025) · Medicine · doi:10.1097/md.0000000000041178 · Cited by 38
Bahadur, A., Arora, H., Ravi, A. K., Naithani, M., Bahurupi, Y., Chaturvedi, J., Ajmani, M., & Mundhra, R. (2021) · Cureus · doi:10.7759/cureus.15510 · Cited by 22
“While Metformin is the classical and most frequently used drug for the treatment of PCOS, recently there is a focus on MI [14,15].”
BackgroundCheraghi, E., Mehranjani, M. S., Shariaatzadeh, M. A., Esfahani, M. H. N., & Ebrahimi, Z. (2014) · PubMed · Cited by 22
Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis
Song, Y. M., Wang, H., Huang, H., & Zhu, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1689553 · Cited by 31
“Metformin has been used in the treatment of PCOS for a long time; however, gastrointestinal side effects, hypoglycemia and an increase in the serum homocysteine levels in some patients taking metformin [35,36].”
BackgroundPhysiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00017-4 · Cited by 34
The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome
Diamanti‐Kandarakis, E., Kandaraki, E., Christakou, C. D., & Panidis, D. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00588.x · Cited by 24
“The potential therapeutic effect of metformin on lipidemic parameters of PCOS patients appears to be multifactorial, but may rely significantly upon its direct actions on classic metabolic tissues (30) (Fig.”
BackgroundInfluentialLi, B., Takeda, T., Tsuiji, K., Kondo, A., Kitamura, M., Wong, T. F., & Yaegashi, N. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.706668 · Cited by 21
“Many reports support the therapeutic usefulness of metformin on reproductive assistance in PCOS and long-term clinical use of metformin does not seems to raise questions of safety and serious adverse effects [23].”
Metformin and Angiogenesis in Cancer - Revisited
Kannarkatt, J., Alkharabsheh, O. A., Tokala, H., & Dimitrov, N. V. (2016) · Oncology · doi:10.1159/000448175 · Cited by 24
Metadata
- Authors
- Palomba, S., Falbo, A., Zullo, F., & Orio, F.
- Affiliations
- Magna Graecia University (IT)
- Parthenope University of Naples (IT)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-12-04
- Volume
- 30
- Issue
- 1
- Pages
- 1-50
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2160472557
- Cited by
- 426
- References
- 491
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 20 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 19 · 2017: 15 · 2016: 18 · 2015: 26 · 2014: 37 · 2013: 40 · 2012: 33
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutial research information system (Parthenope University of Naples) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, insulin sensitization, insulin resistance, menstrual disorders, anovulatory infertility, pregnancy complications, hyperandrogenism, endometrial abnormalities, cardiovascular risk, PCOS prevention, type 2 diabetes
- MeSH terms
- Anovulation, Cardiovascular Diseases, Endometrium, Female, Humans, Hypoglycemic Agents, Menstruation Disturbances, Metformin, Obesity, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Quality of Life, Endometrial Neoplasms, Hyperandrogenism, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.